{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T07:34:34Z","timestamp":1794555274494,"version":"4.9.1"},"reference-count":42,"publisher":"Oxford University Press (OUP)","issue":"4","license":[{"start":{"date-parts":[[2024,7,22]],"date-time":"2024-07-22T00:00:00Z","timestamp":1721606400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,4,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Objectives<\/jats:title>\n                  <jats:p>The optimal duration of immunosuppressive (IS) treatment for lupus nephritis (LN) remains uncertain. We assessed the prevalence and predictors of IS tapering and discontinuation (D\/C) in LN patients.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>Data from 137 inception cohort LN patients were analysed. We examined determinants of flares during tapering and after IS D\/C, D\/C achievement and time to D\/C, and adverse long-term outcomes applying logistic and linear regression models.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>IS tapering was attempted in 111 (81%) patients, and D\/C was achieved in 67.5%. Longer time to achieve complete renal response (CR) [odds ratio (OR): 1.07, P\u2009=\u20090.046] and higher SLEDAI-2K at tapering initiation (OR: 2.57, P\u2009=\u20090.008) were correlated with higher risk of renal flares during tapering. Persistent hydroxychloroquine use (\u22652\/3 of follow-up) (OR: 0.28, P\u2009=\u20090.08) and lower SLEDAI-2K 12\u2009months before IS D\/C (OR: 1.70, P\u2009=\u20090.013) decreased the risk of post-D\/C flares. Adverse outcomes (&amp;gt;30% estimated glomerular filtration rate decline, chronic kidney disease, end-stage renal disease, death) at the end of follow-up (median 124\u2009months) were more frequent in patients with flares during IS tapering (53% vs 16%, P\u2009&amp;lt;\u20090.0038) but did not differ between IS D\/C achievers and non-achievers. In proliferative LN, differences mirrored those in the entire cohort, except for time to D\/C, which occurred 20\u2009months earlier in membranous vs proliferative LN (\u03b2\u2009=\u2009\u221219.8, P\u2009=\u20090.014).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>Earlier CR achievement and lower SLEDAI-2K at tapering initiation prevent flares during IS tapering, while persistent hydroxychloroquine use and lower SLEDAI-2K 12\u2009months before IS D\/C prevent post-D\/C flares. Flares during tapering increase the risk of unfavourable long-term outcomes. Earlier IS D\/C is feasible in membranous LN.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/rheumatology\/keae381","type":"journal-article","created":{"date-parts":[[2024,7,20]],"date-time":"2024-07-20T02:16:51Z","timestamp":1721441811000},"page":"1894-1903","source":"Crossref","is-referenced-by-count":19,"title":["Immunosuppressives discontinuation after renal response in lupus nephritis: predictors of flares, time to withdrawal and long-term outcomes"],"prefix":"10.1093","volume":"64","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3612-9394","authenticated-orcid":false,"given":"Alexandros","family":"Panagiotopoulos","sequence":"first","affiliation":[{"name":"Rheumatology Unit, First Department of Propaedeutic Internal Medicine, Joint Academic Rheumatology Program, Laiko Hospital, Medical School, National & Kapodistrian University of Athens , Athens,","place":["Greece"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9082-6302","authenticated-orcid":false,"given":"Eleni","family":"Kapsia","sequence":"additional","affiliation":[{"name":"Department of Nephrology and Renal Transplantation, Laiko Hospital, Medical School, National and Kapodistrian University of Athens , Athens,","place":["Greece"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3314-3329","authenticated-orcid":false,"given":"Ioannis","family":"El Michelakis","sequence":"additional","affiliation":[{"name":"Department of Nephrology and Renal Transplantation, Laiko Hospital, Medical School, National and Kapodistrian University of Athens , Athens,","place":["Greece"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8202-2892","authenticated-orcid":false,"given":"John","family":"Boletis","sequence":"additional","affiliation":[{"name":"Department of Nephrology and Renal Transplantation, Laiko Hospital, Medical School, National and Kapodistrian University of Athens , Athens,","place":["Greece"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5920-3086","authenticated-orcid":false,"given":"Smaragdi","family":"Marinaki","sequence":"additional","affiliation":[{"name":"Department of Nephrology and Renal Transplantation, Laiko Hospital, Medical School, National and Kapodistrian University of Athens , Athens,","place":["Greece"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5484-2930","authenticated-orcid":false,"given":"Petros P","family":"Sfikakis","sequence":"additional","affiliation":[{"name":"Rheumatology Unit, First Department of Propaedeutic Internal Medicine, Joint Academic Rheumatology Program, Laiko Hospital, Medical School, National & Kapodistrian University of Athens , Athens,","place":["Greece"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2238-0975","authenticated-orcid":false,"given":"Maria G","family":"Tektonidou","sequence":"additional","affiliation":[{"name":"Rheumatology Unit, First Department of Propaedeutic Internal Medicine, Joint Academic Rheumatology Program, Laiko Hospital, Medical School, National & Kapodistrian University of Athens , Athens,","place":["Greece"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,7,22]]},"reference":[{"key":"2025040212102330100_keae381-B1","doi-asserted-by":"crossref","first-page":"2009","DOI":"10.1136\/annrheumdis-2017-211663","article-title":"Survival in adults and children with systemic lupus erythematosus: a systematic review and Bayesian meta-analysis of studies from 1950 to 2016","volume":"76","author":"Tektonidou","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"2025040212102330100_keae381-B2","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1038\/s41572-019-0141-9","article-title":"Lupus nephritis","volume":"6","author":"Anders","year":"2020","journal-title":"Nat Rev Dis Prim"},{"key":"2025040212102330100_keae381-B3","doi-asserted-by":"crossref","first-page":"222","DOI":"10.3899\/jrheum.191094","article-title":"Risk of renal failure within 10 or 20 years of systemic lupus erythematosus diagnosis","volume":"48","author":"Petri","year":"2021","journal-title":"J Rheumatol"},{"key":"2025040212102330100_keae381-B4","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1093\/rheumatology\/kev311","article-title":"The frequency and outcome of lupus nephritis: results from an international inception cohort study","volume":"55","author":"Hanly","year":"2016","journal-title":"Rheumatology"},{"key":"2025040212102330100_keae381-B5","doi-asserted-by":"crossref","first-page":"3248","DOI":"10.1093\/ndt\/gfs073","article-title":"Survival analysis and causes of mortality in patients with lupus nephritis","volume":"27","author":"Yap","year":"2012","journal-title":"Nephrol Dial Transplant"},{"key":"2025040212102330100_keae381-B6","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/S0002-9343(88)80366-8","article-title":"Discontinuation of therapy in diffuse proliferate lupus nephritis","volume":"85","author":"Ponticelli","year":"1988","journal-title":"Am J Med"},{"key":"2025040212102330100_keae381-B7","doi-asserted-by":"crossref","first-page":"142","DOI":"10.3109\/03009749409103047","article-title":"Remission of Lupus Nephritis with Cyclophosphamide and Late Relapses Following Therapy Withdrawal","volume":"23","author":"Pablos","year":"1994","journal-title":"Scand J Rheumatol"},{"key":"2025040212102330100_keae381-B8","doi-asserted-by":"crossref","first-page":"2028","DOI":"10.1002\/art.1780391212","article-title":"Cumulative rate of relapse of lupus nephritis after successful treatment with cyclophosphamide","volume":"39","author":"Ciruelo","year":"1996","journal-title":"Arthritis Rheum"},{"key":"2025040212102330100_keae381-B9","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1046\/j.1523-1755.2000.00832.x","article-title":"Remission, relapse, and re-remission of proliferative lupus nephritis treated with cyclophosphamide","volume":"57","author":"Ioannidis","year":"2000","journal-title":"Kidney Int"},{"key":"2025040212102330100_keae381-B10","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1191\/096120301680416931","article-title":"Therapy with pulse methylprednisolone and short course pulse cyclophosphamide for diffuse proliferative glomerulonephritis","volume":"10","author":"Mosca","year":"2001","journal-title":"Lupus"},{"key":"2025040212102330100_keae381-B11","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1093\/ndt\/gfk073","article-title":"Withdrawal of therapy in patients with proliferative lupus nephritis: long-term follow-up","volume":"21","author":"Moroni","year":"2006","journal-title":"Nephrol Dial Transplant"},{"key":"2025040212102330100_keae381-B12","first-page":"S75","article-title":"What happens after complete withdrawal of therapy in patients with lupus nephritis","volume":"31","author":"Moroni","year":"2013","journal-title":"Clin. Exp. Rheumatol"},{"key":"2025040212102330100_keae381-B13","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.autrev.2017.11.003","article-title":"Can we withdraw immunosuppressants in patients with lupus nephritis in remission? An expert debate","volume":"17","author":"Moroni","year":"2018","journal-title":"Autoimmun Rev"},{"key":"2025040212102330100_keae381-B14","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.2215\/CJN.04830421","article-title":"When and How Is It Possible to Stop Therapy in Patients with Lupus Nephritis A Narrative Review","volume":"16","author":"Moroni","year":"2021","journal-title":"Clin J Am Soc Nephrol"},{"key":"2025040212102330100_keae381-B15","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.1136\/annrheumdis-2022-222435","article-title":"Weaning of maintenance immunosuppressive therapy in lupus nephritis (WIN-Lupus): results of a multicentre randomised controlled trial","volume":"81","author":"Jourde-Chiche","year":"2022","journal-title":"Ann Rheum Dis"},{"key":"2025040212102330100_keae381-B16","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1093\/rheumatology\/keab373","article-title":"Immunosuppressive therapy withdrawal after remission achievement in patients with lupus nephritis","volume":"61","author":"Zen","year":"2022","journal-title":"Rheumatology"},{"key":"2025040212102330100_keae381-B17","doi-asserted-by":"crossref","first-page":"e168","DOI":"10.1016\/S2665-9913(23)00320-X","article-title":"Mycophenolate mofetil withdrawal in patients with systemic lupus erythematosus: a multicentre, open-label, randomised controlled trial","volume":"6","author":"Chakravarty","year":"2024","journal-title":"Lancet Rheumatol"},{"key":"2025040212102330100_keae381-B18","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1002\/art.24545","article-title":"Long-term medical costs and resource utilization in systemic lupus erythematosus and lupus nephritis: a five-year analysis of a large medicaid population","volume":"61","author":"Li","year":"2009","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"2025040212102330100_keae381-B19","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1002\/art.39594","article-title":"Risk of End-Stage Renal Disease in Patients With Lupus Nephritis, 1971\u20132015: a Systematic Review and Bayesian Meta-Analysis","volume":"68","author":"Tektonidou","year":"2016","journal-title":"Arthritis Rheumatol"},{"key":"2025040212102330100_keae381-B20","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1136\/ard-2023-224762","article-title":"EULAR recommendations for the management of systemic lupus erythematosus: 2023 update","volume":"83","author":"Fanouriakis","year":"2024","journal-title":"Ann Rheum Dis"},{"key":"2025040212102330100_keae381-B21","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1016\/j.kint.2023.09.002","article-title":"KDIGO 2024 clinical practice guideline for the management of Lupus Nephritis","volume":"105","author":"Rovin","year":"2024","journal-title":"Kidney Int"},{"key":"2025040212102330100_keae381-B22","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1097\/01.ASN.0000108969.21691.5D","article-title":"The classification of glomerulonephritis in systemic lupus erythematosus revisited","volume":"15","author":"Weening","year":"2004","journal-title":"J Am Soc Nephrol"},{"key":"2025040212102330100_keae381-B23","doi-asserted-by":"crossref","first-page":"1400","DOI":"10.1002\/art.40930","article-title":"2019 European League Against Rheumatism\/American College of Rheumatology classification criteria for systemic lupus erythematosus","volume":"71","author":"Aringer","year":"2019","journal-title":"Arthritis Rheumatol"},{"key":"2025040212102330100_keae381-B24","doi-asserted-by":"crossref","first-page":"1771","DOI":"10.1136\/annrheumdis-2012-201940","article-title":"Joint European League Against Rheumatism and European Renal Association\u2013European Dialysis and Transplant Association (EULAR\/ERA-EDTA) recommendations for the management of adult and paediatric lupus nephritis","volume":"71","author":"Bertsias","year":"2012","journal-title":"Ann Rheum Dis"},{"key":"2025040212102330100_keae381-B25","first-page":"139","article-title":"Kidney Disease: improving Global Outcomes (KDIGO) Glomerulonephritis Work Group. KDIGO clinical practice guideline for glomerulonephritis","volume":"2","author":"Cattran","year":"2012","journal-title":"Kidney Int Suppl"},{"key":"2025040212102330100_keae381-B26","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1002\/art.1780340802","article-title":"Definition, incidence, and clinical description of flare in systemic lupus erythematosus. A prospective cohort study","volume":"34","author":"Petri","year":"1991","journal-title":"Arthritis Rheum"},{"key":"2025040212102330100_keae381-B27","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1002\/art.1780400506","article-title":"The reliability of the Systemic Lupus International Collaborating Clinics\/American College of Rheumatology damage index in patients with Systemic Lupus Erythematosus","volume":"40","author":"Gladman","year":"1997","journal-title":"Arthritis Rheum"},{"key":"2025040212102330100_keae381-B28","first-page":"288","article-title":"Systemic lupus erythematosus disease activity index 2000","volume":"29","author":"Gladman","year":"2002","journal-title":"J. Rheumatol"},{"key":"2025040212102330100_keae381-B29","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.1136\/annrheumdis-2015-207726","article-title":"Definition and initial validation of a Lupus Low Disease Activity State (LLDAS)","volume":"75","author":"Franklyn","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"2025040212102330100_keae381-B30","doi-asserted-by":"crossref","first-page":"e000538","DOI":"10.1136\/lupus-2021-000538","article-title":"2021 DORIS definition of remission in SLE: final recommendations from an international task force","volume":"8","author":"van Vollenhoven","year":"2021","journal-title":"Lupus Sci Med"},{"key":"2025040212102330100_keae381-B31","doi-asserted-by":"crossref","first-page":"e000634","DOI":"10.1136\/lupus-2021-000634","article-title":"Conceptual framework for defining disease modification in systemic lupus erythematosus: a call for formal criteria","volume":"9","author":"van Vollenhoven","year":"2022","journal-title":"Lupus Sci Med"},{"key":"2025040212102330100_keae381-B32","doi-asserted-by":"crossref","first-page":"e003158","DOI":"10.1136\/rmdopen-2023-003158","article-title":"Disease modification achievement in patients with lupus nephritis in a real-life setting: mission impossible?","volume":"9","author":"Panagiotopoulos","year":"2023","journal-title":"RMD Open"},{"key":"2025040212102330100_keae381-B33","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1177\/0961203317726376","article-title":"Sustained complete renal remission is a predictor of reduced mortality, chronic kidney disease and end-stage renal disease in lupus nephritis","volume":"27","author":"Pakchotanon","year":"2018","journal-title":"Lupus"},{"key":"2025040212102330100_keae381-B34","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.3899\/jrheum.101249","article-title":"Longterm Followup After Tapering Mycophenolate Mofetil During Maintenance Treatment for Proliferative Lupus Nephritis","volume":"38","author":"Laskari","year":"2011","journal-title":"J Rheumatol"},{"key":"2025040212102330100_keae381-B35","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1136\/ard-2023-224919","article-title":"Pragmatic targets for moderate\/severe SLE and their implications for clinical care and trial design: sustained DORIS or LLDAS for at least 6 months is sufficient while their attainment for at least 24 months ensures high specificity for damage-free progression","volume":"83","author":"Pitsigavdaki","year":"2024","journal-title":"Ann Rheum Dis"},{"key":"2025040212102330100_keae381-B36","doi-asserted-by":"crossref","first-page":"e584","DOI":"10.1016\/S2665-9913(23)00209-6","article-title":"Impact of low disease activity, remission, and complete remission on flares following tapering of corticosteroids and immunosuppressive therapy in patients with systemic lupus erythematous: a multinational cohort study","volume":"5","author":"Cho","year":"2023","journal-title":"Lancet Rheumatol"},{"key":"2025040212102330100_keae381-B37","doi-asserted-by":"crossref","first-page":"5017","DOI":"10.3390\/jcm11175017","article-title":"Predictors of early response, flares, and long-term adverse renal outcomes in proliferative lupus nephritis: a 100-month median follow-up of an inception cohort","volume":"11","author":"Kapsia","year":"2022","journal-title":"J Clin Med"},{"key":"2025040212102330100_keae381-B38","doi-asserted-by":"crossref","first-page":"809533","DOI":"10.3389\/fmed.2022.809533","article-title":"New Insights Into an Overlooked Entity: long-Term Outcomes of Membranous Lupus Nephritis From a Single Institution Inception Cohort","volume":"9","author":"Kapsia","year":"2022","journal-title":"Front Med"},{"key":"2025040212102330100_keae381-B39","doi-asserted-by":"crossref","first-page":"150","DOI":"10.3899\/jrheum.2022-1200","article-title":"Efforts to better characterize \u201cantiphospholipid antibody nephropathy\u201d for the 2023 ACR\/EULAR antiphospholipid syndrome classification criteria: renal pathology subcommittee report","volume":"51","author":"Barbhaiya","year":"2024","journal-title":"J Rheumatol"},{"key":"2025040212102330100_keae381-B40","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1016\/j.kint.2018.05.021","article-title":"A prospective observational cohort study highlights kidney biopsy findings of lupus nephritis patients in remission who flare following withdrawal of maintenance therapy","volume":"94","author":"De Rosa","year":"2018","journal-title":"Kidney Int"},{"key":"2025040212102330100_keae381-B41","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/j.kint.2019.07.018","article-title":"Kidney biopsy\u2013based management of maintenance immunosuppression is safe and may ameliorate flare rate in lupus nephritis","volume":"97","author":"Malvar","year":"2020","journal-title":"Kidney Int"},{"key":"2025040212102330100_keae381-B42","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1007\/s00005-022-00646-9","article-title":"Treat-to-Target in Lupus Nephritis. What is the Role of the Repeat Kidney Biopsy?","volume":"70","author":"Parodis","year":"2022","journal-title":"Arch Immunol Ther Exp (Warsz)"}],"container-title":["Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/rheumatology\/advance-article-pdf\/doi\/10.1093\/rheumatology\/keae381\/58995811\/keae381.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/rheumatology\/article-pdf\/64\/4\/1894\/58995811\/keae381.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/rheumatology\/article-pdf\/64\/4\/1894\/58995811\/keae381.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,2]],"date-time":"2025-04-02T16:28:10Z","timestamp":1743611290000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/rheumatology\/article\/64\/4\/1894\/7717969"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,22]]},"references-count":42,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2024,7,22]]},"published-print":{"date-parts":[[2025,4,1]]}},"URL":"https:\/\/doi.org\/10.1093\/rheumatology\/keae381","relation":{},"ISSN":["1462-0324","1462-0332"],"issn-type":[{"value":"1462-0324","type":"print"},{"value":"1462-0332","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,4]]},"published":{"date-parts":[[2024,7,22]]}}}